Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies MOUNTAIN VIEW, Calif., Nov. 04 ...
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday ...
Fintel reports that on December 6, 2024, BMO Capital initiated coverage of IGM Biosciences (NasdaqGS:IGMS) with a Outperform recommendation. As of December 3, 2024, the average one-year price ...
Hosted on MSN1mon
BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform RecommendationAverage portfolio weight of all funds dedicated to IGMS is 0.06%, an increase of 80.93%. Total shares owned by institutions decreased in the last three months by 0.30% to 22,732K shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback